Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | $65.160 |
Close | - |
Volume / Avg. | 407.294K / 970.261K |
Day Range | 65.160 - 67.220 |
52 Wk Range | 45.500 - 84.890 |
Market Cap | $6.970B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 42 |
Short Interest | 3.9% |
Days to Cover | 6.95 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Needham on Wednesday, May 8, 2024. The analyst firm set a price target for 90.00 expecting ITCI to rise to within 12 months (a possible 36.33% upside). 37 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $66.015 last updated Today at May 13, 2024 at 3:26 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q2 earnings are confirmed for Thursday, August 1, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.